David Zick, MD
Psychiatry · Bowling Green, OHNPI 1366480576
Payments from drug & device makers
Across 292 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$704
- Alkermes, Inc.$606
- AbbVie$523
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$516
- Teva Pharmaceuticals USA, Inc.$515
- Neurocrine Biosciences, Inc.$491
- plus $2K from 13 others
What the payments were for
- Food & beverage$5,16499%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 52 | $704 |
| Alkermes, Inc. | 30 | $606 |
| AbbVie(2 entities) | 24 | $523 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $516 |
| Teva Pharmaceuticals USA, Inc. | 35 | $515 |
| Neurocrine Biosciences, Inc. | 22 | $491 |
| Lundbeck LLC | 17 | $329 |
| Axsome Therapeutics, Inc. | 13 | $293 |
| Indivior Inc. | 13 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $229 |
| Johnson & Johnson | 12 | $210 |
| Bausch Health US, LLC | 6 | $137 |
| Sunovion Pharmaceuticals Inc. | 15 | $131 |
| Vanda Pharmaceuticals Inc. | 3 | $99 |
| Idorsia Pharmaceuticals US Inc | 4 | $61 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$140
How this compares
$5,211 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 189 | $548,281 |
| Invega TrinzaPaliperidone Palmitate | 34 | $252,486 |
| IngrezzaValbenazine Tosylate | 27 | $209,779 |
| VraylarCariprazine Hcl | 131 | $162,778 |
| AplenzinBupropion Hbr | 37 | $111,676 |
| AristadaAripiprazole Lauroxil | 46 | $94,319 |
| TrintellixVortioxetine Hydrobromide | 129 | $71,553 |
| UzedyRisperidone | 17 | $53,879 |
| Risperdal ConstaRisperidone Microspheres | 26 | $48,830 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $37,056 |
| Aripiprazole | 302 | $36,918 |
| RexultiBrexpiprazole | 24 | $34,950 |
| AuvelityDextromethorphan Hbr/Bupropion | 25 | $26,549 |
| CaplytaLumateperone Tosylate | 11 | $20,743 |
| Clozapine | 235 | $17,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $210 | $849,597249 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $491 | $209,77927 claims |
| AbbVieVraylar, Fetzima | $523 | $168,694143 claims |
| Alkermes, Inc.Aristada, Lybalvi | $606 | $131,37470 claims |
| Bausch Health US, LLCAplenzin | $137 | $111,67637 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $229 | $71,553129 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $515 | $53,87917 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $704 | $34,95024 claims |
| Axsome Therapeutics, Inc.Auvelity | $293 | $26,54925 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $516 | $20,74311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Bowling Green
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.